Quoin Pharmaceuticals, Ltd.
QNRX
$6.97
-$0.18-2.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.85M | 1.70M | 1.42M | 1.74M | 1.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.47M | 5.13M | 4.52M | 4.02M | 3.79M |
| Operating Income | -5.47M | -5.13M | -4.52M | -4.02M | -3.79M |
| Income Before Tax | -5.37M | -5.00M | -4.35M | -3.95M | -3.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.37M | -5.00M | -4.35M | -3.95M | -3.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.37M | -5.00M | -4.35M | -3.95M | -3.70M |
| EBIT | -5.47M | -5.13M | -4.52M | -4.02M | -3.79M |
| EBITDA | -5.45M | -5.11M | -4.50M | -3.99M | -3.77M |
| EPS Basic | -66.36 | -61.79 | -61.02 | -234.94 | -219.93 |
| Normalized Basic EPS | -1.19 | -1.10 | -1.09 | -4.20 | -3.93 |
| EPS Diluted | -66.36 | -61.79 | -61.02 | -235.20 | -220.50 |
| Normalized Diluted EPS | -1.19 | -1.10 | -1.09 | -4.20 | -3.93 |
| Average Basic Shares Outstanding | 2.83M | 2.83M | 2.49M | 588.20K | 588.20K |
| Average Diluted Shares Outstanding | 80.90K | 80.80K | 71.20K | 16.80K | 16.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |